Article
作者: Bonnabau, H. ; Paul, S. ; Thiebaut, Rodolphe ; Launay, Odile ; Preau, M. ; Diallo, A. ; Krief, C. ; Levy, Yves ; Wiedemann, A. ; Delahaye, S. ; Diallo, Alpha ; Couderc, M. ; Hardel, L. ; Tisserand, Pascaline ; Bouakane, A. ; Delobel, P. ; Levy, Y. ; Miloudi, S. ; Bourlet, T. ; Savarieau, H. ; Launay, O. ; Tisserand, P. ; Desaint, C. ; Richert, L. ; Walker, S. ; Durand, Melany ; Hardel, Lucile ; Centlivre, M. ; Lefebvre, Cecile ; Verlinde-Carvalho, M. ; Bauduin, Claire ; Gilbert, C. ; Amri, I. ; Hanot, L. ; Hocini, Hakim ; Thiebaut, R. ; Lucht, F. ; Foucat, E. ; Nedjaai, N. ; Bouvier, M. ; Hejblum, B. ; Rouby, F. ; Foucat, Emile ; Melica, G. ; Dumont, C. ; Poizot-Martin, Isabelle ; Fresard, A. ; Lacabaratz, C. ; Reijonen, K. ; Carcelain, G. ; Krivine, A. ; Allais, F. ; Clavier, E. ; Lelievre, J.-D. ; Honore, S. ; Wiedemann, Aurelie ; Grondin, C. ; Bauduin, C. ; Bodilis, H. ; Chesnel, C. ; Reboud, P. ; Wittkop, L. ; Durand, M. ; Tamalet, C. ; Giroud, A. ; Guillaumat, Lydia ; Hocini, H. ; Guerin, C. ; Fouilloux, P. ; Sommet, A. ; Blengio, F. ; Viard, J.-P. ; Davier, M. ; Hanslik, T. ; Rieux, Veronique ; Lhomme, E. ; Fries, I. ; Rouch, Elodie ; Dominguez, S. ; Zaegel-Faucher, O. ; Rouch, E. ; Lopez, J.-L. ; Lefebvre, C. ; Colin de Verdiere, N. ; Ronat, V. ; Deluca, B. ; Micallef, J. ; Niedziolka, P. Duchet ; Richert, Laura ; Lucht, Frederic ; Arnold, V. ; Loulergue, P. ; Lelievre, Jean-Daniel ; Poizot-Martin, I. ; Rieux, V. ; Perrier, A. ; Lacabaratz, Christine ; Barin, F. ; Ollivier-Yaniv, C. ; Surenaud, M. ; Fagard, C. ; Guillaumat, L. ; Terrier, F. ; Lemoine, F. ; Surenaud, Mathieu ; Hejblum, Boris
AbstractHeterologous prime-boost strategies are of interest for HIV vaccine development. The order of prime-boost components could be important for the induction of T cell responses. In this phase I/II multi-arm trial, three vaccine candidates were used as prime or boost: modified vaccinia Ankara (MVA) HIV-B (coding for Gag, Pol, Nef); HIV LIPO-5 (five lipopeptides from Gag, Pol, Nef); DNA GTU-MultiHIV B (coding for Rev, Nef, Tat, Gag, Env gp160 clade B). Healthy human volunteers (n = 92) were randomized to four groups: 1) MVA at weeks 0/8 + LIPO-5 at weeks 20/28 (M/L); 2) LIPO-5 at weeks 0/8 + MVA at weeks 20/28 (L/M); 3) DNA at weeks 0/4/12 + LIPO-5 at weeks 20/28 (G/L); 4) DNA at weeks 0/4/12 + MVA at weeks 20/28 (G/M). The frequency of IFN-γ–ELISPOT responders at week 30 was 33, 43, 0, and 74%, respectively. Only MVA-receiving groups were further analyzed (n = 62). Frequency of HIV-specific cytokine-positive (IFN-γ, IL-2, or TNF-α) CD4+ T cells increased significantly from week 0 to week 30 (median change of 0.06, 0.11, and 0.10% for M/L, L/M, and G/M, respectively), mainly after MVA vaccinations, and was sustained until week 52. HIV-specific CD8+ T cell responses increased significantly at week 30 in M/L and G/M (median change of 0.02 and 0.05%). Significant whole-blood gene expression changes were observed 2 wk after the first MVA injection, regardless of its use as prime or boost. An MVA gene signature was identified, including 86 genes mainly related to cell cycle pathways. Three prime-boost strategies led to CD4+ and CD8+ T cell responses and to a whole-blood gene expression signature primarily due to their MVA HIV-B component.